by The global Metabolism Drugs Market predominantly involves drugs to treat various metabolism disorders like obesity and thyroid issues. Metabolism drugs address imbalances caused due to slow or fast metabolism by regulating enzymes or hormones. Drugs like anti-obesity medications help weight loss or weight management by decreasing appetite or increasing feelings of fullness. The increasing prevalence of obesity and associated risk of diabetes and heart disease has fueled demand for weight loss drugs. As per WHO, over 650 million adults and over 340 million children and adolescents aged 5-19 were obese in 2016.
The global Metabolism Drugs Market is estimated to be valued at US$ 8169.16 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the metabolism drugs market is the focus on innovative drug delivery systems. Researchers are developing new delivery mechanisms to improve oral bioavailability and patient compliance for existing drug molecules. For example, new sustained or extended-release formulations can maintain therapeutic drug concentrations for longer durations with fewer doses. Similarly, combination therapies aim to provide additive or synergistic benefits. The market also witnesses emergence of novel drug targets. For instance, drugs targeting GLP-1 and peptide YY are under development for weight management. Growing awareness about lifestyle-related diseases and advanced treatment options also drives the demand and adoption of new drug formulations in the market.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in the metabolism drugs market is moderate. Significant capital is required for R&D to develop new drugs and patent protection limits entry.
Bargaining power of buyers: The bargaining power of buyers is high. Buyers have several treatment options to choose from and can negotiate lower prices through large volume purchasing.
Bargaining power of suppliers: The bargaining power of suppliers is moderate. Key raw material suppliers hold some power due to limited availability but customer switching costs are low.
Threat of new substitutes: The threat of new substitutes is moderate. Alternatives like lifestyle changes and supplements provide some substitute options.
Competitive rivalry: Competition in the market is high with the presence of many regional and global players.
Key Takeaways
The Global Metabolism Drugs Market Demand is expected to witness high growth over the forecast period of 2023 to 2030. The market is projected to grow at a CAGR of 7.6% during this period and reach a size of US$ 8169.16 Mn in 2023.
Regional analysis: North America is expected to dominate the global metabolism drugs market during the forecast period. This is attributed to the growing obese population and increasing healthcare expenditure in the region. Asia Pacific is anticipated to showcase the fastest growth over the coming years, led by population growth, rising income levels and changing lifestyles in developing countries such as China and India.
Key players: Key players operating in the metabolism drugs market are Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd’s Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma. These players are focusing on new product launches and partnerships to strengthen their presence in the market.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
